Exploring the application of doggybone DNA to facilitate non-viral gene therapy delivery to hemophilia patients
Cell & Gene Therapy Insights 2023; 9(5), 837–842
Published: 19 July
Carol H Miao
Novel non-viral gene delivery methods have the potential to greatly improve treatment protocols for patients with genetic diseases such as hemophilia.David McCall, Senior Editor at BioInsights, speaks with Principal Investigator at Seattle Children’s Research Institute, Carol Miao, about her work with doggybone DNA (also known as dbDNA™), an optimized DNA platform for non-viral gene transfer. Doggybone DNA is an enzymatic DNA is manufactured in a cell free process using enzymes, rather than bacterial cells. Miao discusses the key benefits to using dbDNA versus plasmid DNA as cargo-carrying transgene expression cassettes.